Despite the assured therapeutic effects of Disitamab Vedotin in patients expressed with HER2-positive, it is believed that Disitamab Vedotin also has anti-tumor effects on tumors with heterogeneous antigen expression due to the bystander effect. The gene discussed is ERBB2; the disease is neoplasm.